Rivaroxaban reduces thromboxane induced platelet aggregation - the forgotten compass arm?

Saved in:
Bibliographic Details
Published inPlatelets (Edinburgh) Vol. 32; no. 8; pp. 1126 - 1128
Main Authors Dannenberg, Lisa, M'Pembele, René, Mourikis, Philipp, Helten, Carolin, Zako, Saif, Ahlbrecht, Samantha, Richter, Hannah, Zikeli, Dorothee, Benkhoff, Marcel, Huhn-Wientgen, Ragnar, Thienel, Manuela, Levkau, Bodo, Kelm, Malte, Petzold, Tobias, Polzin, Amin
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 17.11.2021
Taylor & Francis Group
Subjects
Aggregation
aspirin
Aspirin - pharmacology
Aspirin - therapeutic use
Chronic Disease - drug therapy
Drug Therapy, Combination - methods
Heart Diseases - drug therapy
Humans
major adverse cardiovascular and cerebrovascular events
Platelet Aggregation - drug effects
Platelet Function Tests - methods
platelet inhibition
rivaroxaban
Rivaroxaban - pharmacology
Rivaroxaban - therapeutic use
thromboxane
Thromboxanes - adverse effects
Aggregation
thromboxane
major adverse cardiovascular and cerebrovascular events
platelet inhibition
aspirin
rivaroxaban
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0953-7104
1369-1635
DOI:10.1080/09537104.2021.1905159